<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03891472</url>
  </required_header>
  <id_info>
    <org_study_id>KNW/0022/KB1/71/I/16</org_study_id>
    <nct_id>NCT03891472</nct_id>
  </id_info>
  <brief_title>Clinical Phase II Clinical Study Evaluating the Toxicity and Efficacy of mFOLFIRINOX Associated With SBRT (Stereotactic Radiotherapy) in Patients With Unresectable Locally Advanced Pancreatic Cancer</brief_title>
  <official_title>Clinical Phase II Clinical Study Evaluating the Toxicity and Efficacy of mFOLFIRINOX Associated With SBRT (Stereotactic Radiotherapy) in Patients With Unresectable Locally Advanced Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Silesia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Silesia</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary goal:&#xD;
&#xD;
      Improvement of the therapeutic index by reducing the toxicity of treatment and increasing&#xD;
      local control of the cancer process while evaluating the possibility of conversion to the&#xD;
      surgical status.&#xD;
&#xD;
      Secondary targets:&#xD;
&#xD;
        -  Survival rate (OS) assessment in patients treated with mFOLFIRINOX + SBRT&#xD;
&#xD;
        -  Assessment of quality of life using questionnaires: EQ-5D, EORTC (QLQ-C30) and&#xD;
           pancreatic cancer-specific QLQ PAS module 26&#xD;
&#xD;
        -  Early toxicity &lt;3 months after completion of SBRT treatment.&#xD;
&#xD;
        -  Percentage of local control (1-year)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      STUDY PLAN Patients will receive initial mFOLFIRINOX (6 cycles) chemotherapy, followed by&#xD;
      evaluation of the response to the treatment (imaging and laboratory testing) followed by&#xD;
      SBRT, followed by mFOLFIRINOX chemotherapy.&#xD;
&#xD;
      In case of exclusion of disease progression after 10 weeks +/- 2 weeks after completion of&#xD;
      SBRT, patients will be qualified to surgical treatment to attempt a radical surgical&#xD;
      treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2017</start_date>
  <completion_date type="Actual">July 31, 2019</completion_date>
  <primary_completion_date type="Actual">July 31, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of the therapeutic index.</measure>
    <time_frame>24 months.</time_frame>
    <description>Improvement of the therapeutic index by reducing the toxicity of treatment and increasing local control of the cancer process while evaluating the possibility of conversion to the surgical status.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvement of the overall survival.</measure>
    <time_frame>60 months.</time_frame>
    <description>Improvement of the overall survival by new treatment method.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Cancer of Pancreas</condition>
  <condition>Unresectable Pancreatic Cancer</condition>
  <condition>Chemotherapy Effect</condition>
  <condition>SBRT</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Patients will receive initial chemotherapy, followed by evaluation of the response to the treatment, followed by SBRT, followed by chemotherapy.</intervention_name>
    <description>mFOLFIRINOX &gt; SBRT &gt; mFOLFIRINOX &gt; Surgical Intervention</description>
    <arm_group_label>Arm 1</arm_group_label>
    <other_name>mFOLFIRINOX (Oxaliplatin, Irinotecan, Fluorouracil)</other_name>
    <other_name>SBRT (Stereotactic Body Radiation Therapy)</other_name>
    <other_name>Surgical Intervention (Pancreatectomy)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signing informed consent for treatment.&#xD;
&#xD;
          2. Age&gt; = 18 years.&#xD;
&#xD;
          3. Patients with histopathological diagnosis of adenocarcinoma of the pancreas.&#xD;
&#xD;
          4. Advanced disease referred to as locally advanced definitive non-resetable,&#xD;
             non-metastatic pancreatic cancer.&#xD;
&#xD;
          5. No prior systemic treatment due to pancreatic adenocarcinoma&#xD;
&#xD;
          6. No prior radiotherapy in the abdominal area&#xD;
&#xD;
          7. No prior radical surgical treatment due to pancreatic adenocarcinoma (palliative&#xD;
             surgical procedures such as bypass surgery or biliary tract surgery are acceptable).&#xD;
&#xD;
          8. ECOG 0 or 1.&#xD;
&#xD;
          9. Expected survival time in excess of 12 weeks.&#xD;
&#xD;
         10. Adequate organ performance based on laboratory blood tests.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients diagnosed with other types of pancreatic cancer than adenocarcinomas (eg&#xD;
             neuroendocrine cancer).&#xD;
&#xD;
          2. Advanced disease that allows primary surgical treatment.&#xD;
&#xD;
          3. Borderline pancreatic cancer (BRPC) disease.&#xD;
&#xD;
          4. The presence of metastases.&#xD;
&#xD;
          5. Previous systemic treatment because of pancreatic adenocarcinoma.&#xD;
&#xD;
          6. Preoperative radiotherapy in the abdominal area.&#xD;
&#xD;
          7. Previous radical surgery for pancreatic adenocarcinoma.&#xD;
&#xD;
          8. Large surgical procedure with the exception of diagnostic biopsies within the last 4&#xD;
             weeks after the start of treatment and / or patients who have not fully recovered&#xD;
             after surgery.&#xD;
&#xD;
          9. Heart failure (NYHA Class II, III or IV)&#xD;
&#xD;
         10. Hemodynamic instability in the course of coronary and / or valvular heart disease and&#xD;
             / or hypertension and / or other clinical conditions (eg uncontrolled diabetes&#xD;
             mellitus).&#xD;
&#xD;
         11. Clinically relevant cardiac arrhythmias requiring treatment.&#xD;
&#xD;
         12. Stroke and / or myocardial infarction history within 6 months of inclusion.&#xD;
&#xD;
         13. Respiratory failure associated with other co-morbidities.&#xD;
&#xD;
         14. Serious psychiatric illnesses, which, in the researcher's opinion, could have a&#xD;
             significant negative impact on the safety of the treatment.&#xD;
&#xD;
         15. Other serious accompanying illnesses, which, in the researcher's opinion, could&#xD;
             seriously adversely affect the safety of the treatment.&#xD;
&#xD;
         16. Transplanted organ transplant including allogeneic bone marrow transplant.&#xD;
&#xD;
         17. Positive diagnosis for HBV or HCV indicating acute or chronic infection (for&#xD;
             screening).&#xD;
&#xD;
         18. HIV infection.&#xD;
&#xD;
         19. The period of pregnancy and breastfeeding.&#xD;
&#xD;
         20. Alcoholism or drug abuse.&#xD;
&#xD;
         21. Limited legal capacity.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UCK Katowice</name>
      <address>
        <city>Katowice</city>
        <state>Śląskie</state>
        <zip>40-514</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>March 11, 2019</study_first_submitted>
  <study_first_submitted_qc>March 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2019</study_first_posted>
  <last_update_submitted>November 9, 2019</last_update_submitted>
  <last_update_submitted_qc>November 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Silesia</investigator_affiliation>
    <investigator_full_name>Katarzyna Kuśnierz</investigator_full_name>
    <investigator_title>Investigator</investigator_title>
  </responsible_party>
  <keyword>mFOLFIRINOX</keyword>
  <keyword>SBRT</keyword>
  <keyword>Unresectable Pancreatic Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

